iShares MSCI Emerging Markets

The iShares MSCI Emerging Markets ETF (NYSE Arca: EEM) is the original emerging-markets liquidity vehicle — launched by iShares (BlackRock) in April 2003 and still one of the most heavily-traded emerging-markets products on Wall Street despite holding only a fraction of the assets it once did.

The structural setup: EEM tracks the MSCI Emerging Markets Index, a free-float market-cap weighted basket of roughly 1,250 large- and mid-cap stocks across 24 emerging-market countries. As of 2026, the largest country exposures are China at roughly 24%, Taiwan at 21%, India at 19%, South Korea at 12% and Brazil near 5%. Top single-stock holdings are dominated by TSMC, Tencent, Samsung Electronics, Alibaba and HDFC Bank — a portfolio that is in practice an Asia-tech-heavy fund, not the commodity-and-financials caricature of emerging markets that prevailed twenty years ago.

The competitive problem: EEM charges a 0.70% expense ratio, ten times what Vanguard FTSE Emerging Markets (VWO, 0.07%) and almost eight times what iShares Core MSCI Emerging Markets (IEMG, 0.09%) charge. The result is that EEM lost the bulk of long-term buy-and-hold inflows to its cheaper siblings — IEMG passed EEM in AUM by 2020, and the gap has widened ever since.

What EEM still offers is institutional-grade liquidity and the deepest options market in emerging-markets ETFs. Average daily volume runs near 30 million shares, the bid-ask spread is typically 1 basis point, and the options chain is the only one in the EM-ETF space with weekly expirations, deep open interest and tight implied-vol pricing — which is exactly why hedge funds, prop desks and macro traders still use EEM for tactical exposure and IEMG or VWO for the buy-and-hold sleeve.

2026 setup: emerging markets enter the year with the cheapest valuation gap versus developed markets in two decades (MSCI EM forward P/E 12.5x vs MSCI World 19.8x), a weakening US dollar (DXY down 4% YTD as the Fed cuts), and a Chinese stimulus cycle that finally produced positive credit impulse — three macro drivers that historically front-load EM equity returns.

The smart-money positioning on EEM in 2026 is a tale of two flows: short-term tactical longs on the macro EM thesis, and long-term structural rotations into cheaper IEMG and VWO.

Macro funds positioned for EM cycle: Bridgewater, GMO and Research Affiliates have all published bullish 2026 EM equity outlooks citing valuation gap, dollar peak and China credit impulse. Bridgewater added EM equity overweight in Q4/2025, GMO models EM small-cap at the highest expected real return of any major asset class (6.7% real, 10-year), and Cliff Asness at AQR has flagged EM-vs-DM valuation spread at a 20-year wide.

Options-flow signal: in Q1/2026, EEM saw the largest call-skew compression in five years — implied volatility on 25-delta calls fell below 25-delta puts for the first time since 2017, meaning options market makers stopped charging fear-premium for EM upside. Historically, that skew flip preceded 18-month EM outperformance windows (2003, 2009, 2017).

Holdings flow: David Tepper (Appaloosa) added Alibaba and BABA in Q4/2025 — both top-15 EEM holdings. Michael Burry exited his EEM put position in Q3/2025 (he was short EEM via puts from 2023). Howard Marks at Oaktree has been incrementally allocating to EM debt and equity since mid-2025, citing valuation discount and dollar mean reversion.

EEM trades at NAV by structural design — the iShares creation/redemption mechanism keeps the trading price within 1-3 basis points of net asset value during normal market conditions. The relevant valuation framework is therefore not the ETF wrapper but the underlying MSCI Emerging Markets Index.

MSCI EM forward P/E sits at 12.5x as of mid-2026 — versus a 10-year median of 13.2x and versus MSCI World at 19.8x. The gap to developed markets is the widest in absolute terms since the 2003-2004 cycle. MSCI EM trailing P/B is 1.6x (vs 10-year median 1.7x) and forward dividend yield is 2.9% (vs MSCI World 1.7%). On every standard multiple, EM trades at a structural discount to DM that is at or near the 20-year extreme.

The valuation does not require any mean-reversion thesis to deliver a base-case return. At a constant 12.5x forward P/E, EM EPS growth of 9% (Bloomberg consensus, FY2026-FY2028) and 2.9% dividend yield delivers a 11.9% gross annual return in local currency. Layer on a 3-4% annual dollar weakness (Fed cuts, fiscal-deficit pressure, dollar-mean-reversion thesis) and the USD total return base case is 14-16% per year over the 2026-2028 window.

Compared to peers: EEM's 0.70% expense ratio drags 11.9% gross to 11.2% net — versus VWO 11.9% gross to 11.83% net or IEMG 11.9% gross to 11.81% net. Over 5 years, that is a 350-bps compounding gap that purely accrues to fee savings in VWO or IEMG.

1. 2026-Q2: MSCI semi-annual index review (May 2026) — typical 0.5-1% portfolio turnover and any China A-share inclusion-factor change is announced. Watch for further IEMG vs EEM AUM divergence reports.
2. 2026-Q3: China Central Economic Work Conference (October 2026) — expected to set 2027 GDP target and any further stimulus measures. A target above 5% would solidify the EM credit-impulse thesis.
3. 2026-Q4: Fed terminal-rate communication. If the December 2026 SEP shows Fed funds rate below 3.5%, the DXY downside extends and EM equity excess return continues. If hawkish, the EM thesis pauses.
4. 2027-Q1: TSMC 2nm production ramp begins (expected early 2027). Apple, NVIDIA and Qualcomm 2nm orders confirmed Q4/2026. Direct earnings tailwind for TSMC (9% of EEM).
5. 2027-Q2: India national elections (May 2027). A Modi/BJP third-term confirmation supports the structural India bull case (19% of EEM). An NDA loss would be a multi-month negative for India weighting.

I look at EEM and my honest view is: this is the wrong ETF for 95% of investors who own it. If you want long-term emerging-markets exposure and you are paying 0.70% per year, you are voluntarily giving up roughly 60 basis points of annual return forever. Over a 10-year compound, that is 6-7% of your final NAV gone to BlackRock for no incremental benefit over VWO or IEMG.

The honest case for EEM is narrow: you are a tactical trader who values 1-basis-point spreads and the deepest options chain in EM, or you are a hedge fund that needs to express a short-dated EM view with weekly options expirations. For those use cases, EEM is the best EM ETF on the planet. For everyone else, VWO at 0.07% or IEMG at 0.09% delivers the same MSCI/FTSE EM exposure at one-tenth the cost.

That said, the broader EM cycle question is more interesting than the ETF-choice question. We are entering 2026 with the widest EM-vs-DM valuation gap in 20 years, a weakening US dollar, and a finally-positive China credit impulse. These three macro drivers have, in every prior cycle, preceded 3-5 years of EM outperformance over developed markets. I personally have material EM exposure in my portfolio — but not through EEM. I use IEMG for the core US-domiciled allocation and direct ADR holdings in Tencent, TSMC and Samsung for the high-conviction single-name exposure.

For a German investor reading this: in EUR terms, even more importantly than the EEM-vs-IEMG cost question, the FX hedging question matters. EM equity returns can be 40-60% FX-driven over multi-year periods, and a USD-denominated US-domiciled EM ETF adds another USD-EUR FX layer. For long-term EUR-funded EM exposure, consider iShares Core MSCI EM IMI UCITS (IS3N.DE) at 0.18% TER — UCITS-compliant, EUR-denominated, and broader than EEM.